EU medtech reimbursement and HTA policy: an overview of key issues and how they impact industry
This article was originally published in Clinica
Executive Summary
In the first article of Clinica's new series on EU medtech reimbursement and health technology assessment, Dr Mark Charny, managing director of UK-based consultancy Translucency, outlines the current issues and challenges medtech companies are facing when seeking to bring innovative products into the EU